Benjamin Hadida MSc, MBA

Benjamin Hadida is the Co-founder & CEO of Exeliom Biosciences, a clinical-stage immunotherapy company based in France. Exeliom is advancing EXL01, a first-in-class, oral, microbiome-derived immunomodulator that targets NOD2 to enhance responses to immune checkpoint inhibitors and restore immune balance in inflammatory disease. Under Benjamin’s leadership, the company has raised $29M+, built a pilot manufacturing unit, and launched multiple Phase 2 trials across oncology, inflammatory bowel diseases, and infectious diseases. His background spans investment banking (UBS), venture capital (Pacific Channel), pharma regulatory (Amgen), biotech operations (Theravectys), and academic research (Vision Institute, Paris). He holds an MSc in Management (ESSEC – Grand Ecole) and an MSc in Molecular & Cellular Biology (Sorbonne University).